Verastem Oncology has granted stock options to purchase 73,000 shares of its common stock to eight new employees and awarded 218,265 restricted stock units to nineteen new employees. The stock options have an exercise price of $6.88 per share, based on the closing price on January 6, 2026. Vesting for both stock options and restricted stock units is structured so that 25% vests on the one-year anniversary of each employee’s hire date, with the remaining shares vesting in equal quarterly amounts over the next three years, contingent upon continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112749150) on January 12, 2026, and is solely responsible for the information contained therein.